Restaino A, Traina V, Putignano G, Fanizza G, Miniello G, Vicino M, Malvasi A
I Gynaecological Institute, University of Bari, Italy.
Eur J Gynaecol Oncol. 1988;9(1):30-2.
The Authors studied the presence of some markers in different gynaecological tumours, by radioimmunoassay. Beta-HCG, 1-alfa-FP, CA 125, GICA and TPA were assayed in 76 patients. Eight of the patients were affected by CIN III, 38 presented a cervical carcinoma (10 at stage I, 14 at stage II, 10 at stage III, 4 at stage IV); 14 patients had an endometrial adenocarcinoma (3 at stage I, 7 at stage II, 2 at stage III and II at stage IV); 12 cases consisted of an ovarian carcinoma with 2 patients at stage I, 5 at stage II and 5 at stage III; 2 patients had a peritoneal diffusion, whereas two women presented a vulvar carcinoma; the control group was formed by 10 patients with no malignant or benign pathology. The results show that tumoral markers, studied in the blood of patients affected by malignant gynaecological tumours, represent a great advantage in the evaluation of both the response to the therapy and of an eventual remission or tumoral recurrence.
作者通过放射免疫分析法研究了不同妇科肿瘤中某些标志物的存在情况。对76例患者检测了β-HCG、甲胎蛋白、CA 125、免疫层析法和组织多肽抗原。其中8例患者为III级宫颈上皮内瘤变，38例为宫颈癌（I期10例，II期14例，III期10例，IV期4例）；14例患者为子宫内膜腺癌（I期3例，II期7例，III期2例，IV期2例）；12例为卵巢癌，其中I期2例，II期5例，III期5例；2例有腹膜播散，2例为外阴癌；对照组由10例无恶性或良性病变的患者组成。结果表明，在患有恶性妇科肿瘤的患者血液中研究的肿瘤标志物，在评估治疗反应以及最终缓解或肿瘤复发方面具有很大优势。
